Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03478462




Registration number
NCT03478462
Ethics application status
Date submitted
20/03/2018
Date registered
27/03/2018
Date last updated
17/05/2023

Titles & IDs
Public title
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Scientific title
An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Secondary ID [1] 0 0
DCL-17-001
Universal Trial Number (UTN)
Trial acronym
CLOVER-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pediatric Solid Tumor 0 0
Pediatric Lymphoma 0 0
Pediatric Brain Tumor 0 0
DIPG 0 0
Neuroblastoma 0 0
Ewing Sarcoma 0 0
Rhabdomyosarcoma 0 0
Osteosarcoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Sarcoma (also see 'Bone') - soft tissue
Cancer 0 0 0 0
Bone
Cancer 0 0 0 0
Brain
Cancer 0 0 0 0
Neuroendocrine tumour (NET)
Cancer 0 0 0 0
Children's - Other

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CLR 131

Experimental: CLR 131 - CLR 131 intravenous administration


Treatment: Drugs: CLR 131
IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with dose limiting toxicities (DLT)
Timepoint [1] 0 0
up to 64 days
Secondary outcome [1] 0 0
Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults
Timepoint [1] 0 0
until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
Secondary outcome [2] 0 0
Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults
Timepoint [2] 0 0
through Day 85
Secondary outcome [3] 0 0
Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults
Timepoint [3] 0 0
up to 22 days post initial infusion
Secondary outcome [4] 0 0
Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults
Timepoint [4] 0 0
1 month to 5 years
Secondary outcome [5] 0 0
Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults
Timepoint [5] 0 0
1 month to 5 years
Secondary outcome [6] 0 0
Determine dosimetry of CLR 131 in children, adolescents, and young adults
Timepoint [6] 0 0
up to 15 days post initial infusion

Eligibility
Key inclusion criteria
All Patients

- Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g.,
neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain
tumors that are clinically or radiographically suspected to be relapsed, refractory,
or recurrent for which there are no standard treatment options with curative
potential. Note: patients with diffuse intrinsic pontine glioma (DIPG) may enroll
without histological or cytological confirmation.

- = 2 years of age and = 25 years of age at time of consent/assent

- If = age 16 years, Karnofsky performance status of = 60. If < age 16 years, Lansky
performance status = 60

- Platelets = 75,000/µL (last transfusion, if any, must be at least 1 week prior to
study registration, and, unless deemed medically necessary, no transfusions are
allowed between registration and dosing)

- Absolute neutrophil count = 750/µL

- Hemoglobin = 8 g/dL (last transfusion must be at least 1 week prior to study
registration, and, unless deemed medically necessary, no transfusions are allowed
between registration and dosing)

- Using the bedside Schwartz formula, estimated GFR (creatinine clearance) > 60
ml/min/1.73m2

- Alanine aminotransferase < 3 × ULN

- Bilirubin < 2 × ULN

- Patients who have undergone autologous or allogeneic bone marrow transplant must be at
least 3 months from transplant.

- Patients enrolling at total dose levels > 30 millicurie (mCi)/m2 must have
availability or ability to collect an autologous hematopoietic stem cell back-up
product prior to CLR 131 administration. At minimum, 2 x 10^6/kg cryopreserved CD34+
cells must be available.

- Patient or his or her legal representative is judged by the Investigator to have the
initiative and means to be compliant with the protocol.

Patients with Pediatric Solid Tumor or Lymphoma

- At least 1 measurable lesion with longest diameter of at least 10 mm. Patients with a
lesion(s) that are determined to be Metaiodobenzylguanidine (MIBG) or positron
emission tomography (PET) positive may be enrolled at the investigator's discretion,
even if not associated with a measurable lesion of at least 10 mm. Patients with
neuroblastoma who have detectable disease may enroll provided they meet the
requirements of the International Neuroblastoma Response Criteria.

- Patients with known brain metastases must have completed any radiotherapy or systemic
treatments for brain metastases prior to enrollment; by investigator assessment be
considered stable with no new signs or symptoms for at least 1 month, and on a stable
dose of steroids (unchanged for three weeks prior to registration or on a steroid
tapering regimen).

Patients with Recurrent or Refractory Brain Tumors

- At least 1 measurable lesion with longest diameter of at least 10 mm on any imaging
sequence.

- Patients with previously known neurological deficits must be clinically stable at time
of enrollment and able to complete all study related procedures. Patients with
documented or newly diagnosed neurological deficits will be enrolled at the
investigator's discretion.

- If patient receives steroids for neurological symptom control, the dose must be stable
(unchanged for three weeks prior to registration) or on a steroid tapering regimen.
Initiation of steroids per routine care immediately prior to CLR 131 dosing is
acceptable.
Minimum age
2 Years
Maximum age
25 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients receiving active treatment for central nervous system metastases or those
that are likely to require active treatment during anticipated participation in this
trial. Patients with stable brain metastases treated with steroids may enroll at the
investigator's discretion

- For solid tumor and lymphoma patients only, central nervous system involvement unless
previously treated with surgery, systemic therapy, or radiotherapy with the patient
neurologically stable. Patients with metastatic brain tumors that have been previously
treated are allowed, provided the patient is neurologically stable (determined at the
investigator's discretion).

- Antitumor therapy or investigational therapy, within 2 weeks of dosing. For certain
types of radiation (craniospinal, total abdominal, whole lung [spot irradiation to
skull-based metastases is not considered craniospinal radiation for the purposes of
this study]), at least 3 months must have elapsed. No washout is required for
palliative focal radiation. NOTE: Patients participating in non-interventional
clinical trials (i.e., non-drug) are allowed to participate in this trial

- Patients previously treated with iodine-131 (131I)-MIBG who have already received a
cumulative I-131 dose > 54 mCi/kg or who would exceed 54 mCi/kg by participating in
this trial, are not eligible.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/04/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2024
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Children's Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
New York
Country [3] 0 0
United States of America
State/province [3] 0 0
North Carolina
Country [4] 0 0
United States of America
State/province [4] 0 0
Ohio
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
United States of America
State/province [6] 0 0
Wisconsin
Country [7] 0 0
Canada
State/province [7] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Cellectar Biosciences, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or
refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain
tumors for which there are no standard treatment options with curative potential.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03478462
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jarrod Longcor
Address 0 0
Cellectar Biosciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03478462